Claim OwnershipPharmaceutical Executive
Subscribed: 154Played: 3,292
Subscribe
Description
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
184 Episodes
Reverse
In today’s Pharmaceutical Executive Daily, we will recap the top stories of the week, exploring the current state of the GLP-1 market, review major pharmaceutical layoffs shaping 2025, and cover Pfizer’s response to political pressure on COVID-19 vaccine safety evidence.
In today’s Pharmaceutical Executive Daily, we cover political pressure on Moderna and Novavax to release COVID-19 vaccine evidence, a deep dive into the evolving GLP-1 market, and Sanofi’s share decline following disappointing Phase III results for Amlitelimab.
In today’s Pharmaceutical Executive Daily, we cover Pfizer’s response to political pressure over COVID-19 vaccine safety data, Cheryl Reicin’s outlook on future GLP-1 investment, and Novartis’ $5.2 billion acquisition of Argo Biopharmaceuticals.
In a turbulent era for biopharma, leadership demands clarity, resilience, and adaptability. In this candid podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, shares high-level insights on what CEOs can do to thrive amid the disruption—from regulatory agility to cultural resilience. The corporate strategy expert explains why the best leaders are the best learners—and how prioritization, honesty, and boldness will separate those who merely survive from those who shape the industry’s future.
In this week’s Pharmaceutical Executive Weekly, we cover CSL’s decision to cut 15% of its U.S. workforce and close 22 plasma centers, Pfizer’s Phase 3 trial failure in sickle cell disease, and Eli Lilly’s new LillyDirect program expanding full-dose Zepbound access for obesity patients.
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, discusses strategies to address underrepresentation in phase III psoriasis trials. She also talks about Takeda's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to help improve engagement, address operational barriers by incorporating multicultural imagery, and prioritize sites with diverse patient demographics. She also explains how they've enhanced investigator diversity through educational sessions and multilingual toolkits, and how Takeda aims to expand these efforts globally.
In this Pharmaceutical Executive podcast epsiode, Peter Ax, Founder & CEO of UpScriptHealth, discusses:
The impact of tariffs on the pharmaceutical industry, highlighting branded and generics medications
How tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts.
How digital health platforms, like UpScriptHealth, can help reduce friction and costs in healthcare, potentially offsetting tariff impacts
The importance of telehealth in ensuring medication availability
Strategic partnerships between digital health platforms and pharma companies to improve patient care and access
and more
In this episode of the Pharmaceutical Executive podcast, Jennifer Butler, Chief Commercial Officer of Pleio, discusses:
The threat of misinformation to public health and how emotional appeal plays a part
Where patients are turning for trustworthy health information
Strategies that can be used to verify information
Pharma's role in helping to ensure patients have access to health insights they can trust
Why the industry is turning to peer-to-patient platforms, trusted patient communities, and pharmacies to educate patients
What kind of role regulatory agencies should play in the battle against misinformation
and much more!
Check out our new look and read our February issue here: https://www.pharmexec.com/journals/pharmaceutical-executive/pharmaceutical-executive-february-2025
In this episode of the Pharmaceutical Executive Podcast, CEO and Founder of Sooth, Ian Baer, is back to discuss:
The growing distrust in social media
Why people trust friends and influencers over companies
The EMA's departure from X
Concerns about information accessibility
The healthcare industry's trust gap
"Dark Social"
and SO MUCH MORE!
Pharmaceutical Executive has a brand new look! Click through our February issue here: https://www.pharmexec.com/journals/pharmaceutical-executive/pharmaceutical-executive-february-2025
In this episode of the Pharmaceutical Executive podcast, Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence. By utilizing patient-level data and predictive modeling, AI can identify individual needs and preferences, tailoring interventions to optimize treatment outcomes. This personalized approach addresses the common challenges of medication non-adherence and improves patient outcomes. The discussion highlights the importance of ethical considerations and data privacy when leveraging AI in healthcare. By focusing on patient well-being and using AI responsibly, healthcare providers can significantly enhance patient experiences and improve overall health outcomes.
In this episode of the Pharmaceutical Executive podcast, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses the challenges of addressing fertility misinformation on social media. He emphasizes the importance of providing accurate and reliable information and encourages patients to consult with healthcare professionals. He also discusses the ethical considerations of using social media to share personal and professional experiences in the field of fertility and so much more!
In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer, and much more.
UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss:
Counterfeit weight loss drugs (particularly fake Ozempic) and potential health risks
What can be done to raise awareness among consumers about the dangers of counterfeit medications
Ways increase access to legitimate weight loss medications, especially for those in underserved communities
and much more!
Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is they're positioning to capitalize on the unmet needs in other specific therapeutic areas, their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.
In this episode of the Pharmaceutical Executive podcast, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses:
The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study
The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make
Specific efforts Organon is undertaking to invest in research, education, and its pipeline to focus on critical areas of need in maternal health
How her in-practice experience as an OB-GYN are informing Organon's strategic approach to addressing maternal health challenges
and more!
Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts and the main factors that are contributing to the closures of both large and independent pharmacies, what alternative solutions can help ensure continued access to medications for all Americans (particularly those in underserved communities), some potential long term consequences if these pharmacy closures continue, and so much more
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
What needs to be done for GLP-1s to be covered
Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
Advice for investors and financiers who are considering entering the weight-loss medication market
Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
Link to Honeycomb Health video: https://www.pharmexec.com/view/going-beyond-visuals-to-connect-with-diverse-audiences
Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more.
In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
Featured in this episode are:
Emma Banks, CEO, ramarketing
Jill Jaroch, Senior Director, Women’s Health & Urology Marketing, Astellas
Marie Teil, Global Head, UCB’s Women of Childbearing Age Program
Julia Lakeland, Chief Product Office, uMotif
If you enjoyed this episode of our podcast, we encourage you to seek out the longer version of each of these videos—Linked on our website!
Comments
Download from Google Play
Download from App Store
United States